Clinical Trial

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

Study acronym: EMPOWER-1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.
Protocol Amendment History 3 changes
notable Trial sites expanded: 26 -> 32 locations 2026-06-13
notable Trial sites expanded: 19 -> 26 locations 2026-05-21
notable Trial sites expanded: 3 -> 19 locations 2026-04-23
Trial Details
NCT Number NCT07456696
Lead Sponsor Transcend Therapeutics
Conditions Post Traumatic Stress Disorder
Enrollment 300 participants
Start Date 2026-04-02
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-12